Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Tony Mok; Yi‐Long Wu; Myung‐Ju Ahn; Marina Chiara Garassino; Hye Ryun Kim; Suresh S. Ramalingam; Frances A. Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S.M.E. Theelen; Chee Khoon Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A. Papadimitrakopoulou

doi:10.1056/nejmoa1612674

December 6, 2016New England Journal of MedicineOpen Access

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy of osimertinib compared with platinum-based therapy plus pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer whose disease progressed during first-line EGFR-TKI therapy.
Interventional randomized trial (AURA3; ClinicalTrials.gov number, NCT02151981) in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
Patients with progression on prior first-line EGFR-TKI therapy, including individuals with central nervous system metastases, received either osimertinib or platinum therapy plus pemetrexed.
Osimertinib produced significantly greater clinical efficacy compared to platinum therapy plus pemetrexed.
Superior treatment efficacy with osimertinib was also observed in the subgroup of patients with central nervous system metastases.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Demonstrates superior efficacy of osimertinib over platinum-pemetrexed in EGFR T790M-positive advanced lung cancer, highlighting an effective targeted treatment after initial therapy.

Abstract

Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy. (Funded by AstraZeneca; AURA3 ClinicalTrials.gov number, NCT02151981 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mok et al. (2016) studied this question.

synapsesocial.com/papers/69d9276fe0d31bb747836007 https://doi.org/10.1056/nejmoa1612674

View Full Paper

Ask AI

Bookmark

Share

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading